RECENT FUNDING ROUNDS
| Company | Country | Profile | Funding round | Value | Date | |
|---|---|---|---|---|---|---|
|
Atom Limbs Inc | Innovator in prosthetic technology. | SAFE | |||
|
Modern Healthcare Inc | Series B | USD 31,000,000 | |||
|
Gilgamesh Pharmaceuticals Inc | Novel psychedelic-Inspired therapeutics for treating mental illness. | Seed | |||
|
Digi-Prex | Online subscription pharmacy that deliver patients with chronic diseases their prescriptions. | Seed | USD 5,500,000 | ||
|
Babylon Health | Series C | USD 550,000,000 | |||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Shire PLC | Acquisition | ||||
|
1life Healthcare Inc | A healthcare company focuses on designing innovative health care solutions. | Series C | USD 220,000,000 | ||
|
|
Modern Healthcare Inc | Seed | USD 2,300,000 | |||
|
Cambridge Cancer Genomics Ltd | CCG.ai empowers clinicians to make personalised treatment strategies. | Seed | |||
|
Ginkgo Bioworks Inc | DNA design company. | Series D | USD 275,000,000 | ||
|
|
4C Medical Technologies Inc | Medical device company developing minimally invasive therapies for structural heart disease. | Convertible Note | USD 8,000,000 | ||
|
|
ABI Health | Seed | USD 1,500,000 | |||
|
|
Babylon Health | Series B | USD 47,000,000 | |||
|
NBE-Therapeutics AG | Biotech company focused on developing antibody-based treatments for cancer patients. | Series B | CHF 20,000,000 | ||
|
|
Ginkgo Bioworks Inc | DNA design company. | Series C | USD 100,000,000 | ||
|
|
Babylon Health | Series A | USD 25,000,000 | |||
|
|
1life Healthcare Inc | A healthcare company focuses on designing innovative health care solutions. | N/A | USD 65,000,000 | ||
|
|
InterMune Inc | Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. | Acquisition | USD 8,300,000,000 | ||
|
|
Shire PLC | Acquisition | USD 54,800,000,000 | |||
|
|
ViroPharma Inc | Provider of life-saving medicines for life-threatening diseases. | Acquisition | USD 495,000,000 |